167 related articles for article (PubMed ID: 33278335)
1. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing warfarin dose requirements in African-Americans.
Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
[TBL] [Abstract][Full Text] [Related]
4. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
[TBL] [Abstract][Full Text] [Related]
5. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
6. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Limdi NA; Beasley TM; Crowley MR; Goldstein JA; Rieder MJ; Flockhart DA; Arnett DK; Acton RT; Liu N
Pharmacogenomics; 2008 Oct; 9(10):1445-58. PubMed ID: 18855533
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
10. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.
Liu N; Irvin MR; Zhi D; Patki A; Beasley TM; Nickerson DA; Hill CE; Chen J; Kimmel SE; Limdi NA
Pharmacogenomics; 2017 Jul; 18(11):1059-1073. PubMed ID: 28686080
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of variability in warfarin response after the dose-titration phase.
Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM
Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229
[TBL] [Abstract][Full Text] [Related]
13. Genetic and clinical predictors of warfarin dose requirements in African Americans.
Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
[TBL] [Abstract][Full Text] [Related]
14. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
17. Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients.
Ndadza A; Cindi Z; Makambwa E; Chimusa E; Wonkam A; Kengne AP; Ntsekhe M; Dandara C
OMICS; 2019 Jan; 23(1):36-44. PubMed ID: 30566377
[TBL] [Abstract][Full Text] [Related]
18. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
Nagai R; Ohara M; Cavallari LH; Drozda K; Patel SR; Nutescu EA; Perera MA; Hernandez W; Kaneko N; Hibiya M; Takahashi H
Pharmacogenomics; 2015; 16(3):217-25. PubMed ID: 25712185
[TBL] [Abstract][Full Text] [Related]
20. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Asiimwe IG; Zhang EJ; Osanlou R; Krause A; Dillon C; Suarez-Kurtz G; Zhang H; Perini JA; Renta JY; Duconge J; Cavallari LH; Marcatto LR; Beasly MT; Perera MA; Limdi NA; Santos PCJL; Kimmel SE; Lubitz SA; Scott SA; Kawai VK; Jorgensen AL; Pirmohamed M
Clin Pharmacol Ther; 2020 Jun; 107(6):1420-1433. PubMed ID: 31869433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]